Skip to Content
Merck
  • Low-dose radiation pretreatment improves survival of human ceiling culture-derived proliferative adipocytes (ccdPAs) under hypoxia via HIF-1 alpha and MMP-2 induction.

Low-dose radiation pretreatment improves survival of human ceiling culture-derived proliferative adipocytes (ccdPAs) under hypoxia via HIF-1 alpha and MMP-2 induction.

Biochemical and biophysical research communications (2015-06-19)
Naoki Adachi, Yoshitaka Kubota, Kentarou Kosaka, Shinsuke Akita, Yoshitarou Sasahara, Tomoe Kira, Masayuki Kuroda, Nobuyuki Mitsukawa, Hideaki Bujo, Kaneshige Satoh
ABSTRACT

Poor survival is a major problem of adipocyte transplantation. We previously reported that VEGF and MMPs secreted from transplanted adipocytes are essential for angiogenesis and adipogenesis. Pretreatment with low-dose (5 Gy) radiation (LDR) increased VEGF, MMP-2, and HIF-1 alpha mRNA expression in human ceiling culture-derived proliferative adipocytes (hccdPAs). Gene expression after LDR differed between adipose-derived stem cells (hASCs) and hccdPAs. Pretreatment with LDR improved the survival of hccdPAs under hypoxia, which is inevitable in the early stages after transplantation. Upregulation of VEGF and MMP-2 after LDR in hccdPAs is mediated by HIF-1 alpha expression. Our results suggest that pretreatment with LDR may improve adipocyte graft survival in a clinical setting through upregulation of VEGF and MMP-2 via HIF-1 alpha.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human HIF1A
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinone, absolute, over molecular sieve (H2O ≤0.04%), ≥99.5% (GC)
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinone, ≥99.0% (GC)
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinone, reagent grade
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Hif1a